Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03734393
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : January 24, 2019
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications

Condition or disease Intervention/treatment Phase
Hiv Other: HIVD+/R+ Phase 2

Detailed Description:
This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-). Those participants who have accepted an HIVD- organ will be randomized to be followed in the full study or followed in the nested observational group

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
Actual Study Start Date : January 4, 2019
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: HIV D+/R+
HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
Other: HIVD+/R+
Liver from an HIV-infected deceased donor

No Intervention: HIVD-/R+
HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
No Intervention: HIVD-/R+ (observational)
HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120



Primary Outcome Measures :
  1. Time to first death or graft failure or serious adverse event (SAE) or HIV breakthrough or opportunistic infection as a composite measure [ Time Frame: From date of transplant through administrative censorship at study completion, up to 4 years ]
    Time (in days) to first of any of the following events: death or graft failure or SAE or HIV breakthrough or opportunistic infection


Secondary Outcome Measures :
  1. Time to Pre-transplant mortality [ Time Frame: From date of enrollment to date of transplant or death of any cause, whichever comes first, assessed up to 4 years ]
    Time (in days) to mortality while enrolled before transplant (survival framework)

  2. Graft Failure as assessed by Time to first occurrence of mortality or re-transplant or return to maintenance dialysis [ Time Frame: From date of transplant through administrative censorship at study completion, up to 4 years ]
    Time (in days) to mortality or re-transplant or return to maintenance dialysis (survival framework)

  3. 1-year acute liver rejection [ Time Frame: From date of transplant to end of year 1 ]
    Proportion of recipients who experience acute rejection as measured by biopsy using Banff 2016 comprehensive Update for antibody mediated rejection and Banff 1997 criteria for acute cellular rejection, liver.

  4. 2-year acute liver rejection [ Time Frame: From date of transplant to end of year 2 ]
    Proportion of recipients who experience acute rejection as measured by biopsy using Banff 2016 comprehensive Update for antibody mediated rejection and Banff 1997 criteria for acute cellular rejection, liver.

  5. 3-year acute liver rejection [ Time Frame: From date of transplant to end of year 3 ]
    Proportion of recipients who experience acute rejection as measured by biopsy using Banff 2016 comprehensive Update for antibody mediated rejection and Banff 1997 criteria for acute cellular rejection, liver.

  6. Number of graft rejections in liver transplant [ Time Frame: From date of transplant to end of year 3 ]
    Cumulative incidence of acute rejection (survival framework) as measured by biopsy using Banff 2016 comprehensive Update for antibody mediated rejection and Banff 1997 criteria for acute cellular rejection, liver.

  7. 6-month acute kidney rejection in simultaneous liver/kidney transplant recipients [ Time Frame: From date of transplant to 6 months post transplant ]
    Proportion of recipients who experience acute rejection as measured by biopsy using Banff 2015 criteria: Borderline changes: 'Suspicious' for acute T-cell mediated rejection.This category is used when no intimal arteritis is present, but there are foci of mild tubulitis (t1, t2, or t3) with minor interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis. Acute T-cell mediated rejection:Grade from IA defined as cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of moderate tubulitis (t2) to III defined as cases with 'transmural' arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation (v3)

  8. 1-year acute kidney rejection in simultaneous liver/kidney transplant recipients only [ Time Frame: From date of transplant to end of year 1 ]
    Proportion of recipients who experience acute rejection as measured by biopsy using Banff 2015 criteria: Borderline changes: 'Suspicious' for acute T-cell mediated rejection.This category is used when no intimal arteritis is present, but there are foci of mild tubulitis (t1, t2, or t3) with minor interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis. Acute T-cell mediated rejection:Grade from IA defined as cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of moderate tubulitis (t2) to III defined as cases with 'transmural' arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation (v3)

  9. Number of Non-alcoholic fatty liver (NAFL) [ Time Frame: From date of transplant through end of follow-up, up to 3 years ]
    Cumulative incidence of NAFL as measured by biopsy and transient elastography with controlled attenuation parameter for steatosis

  10. Number of steatohepatitis (NASH) [ Time Frame: From date of transplant through end of follow-up, up to 3 years ]
    Cumulative incidence of NASH as measured by biopsy and transient elastography with controlled attenuation parameter for steatosis

  11. Trajectory of recipient Cluster of Differentiation (CD4) count over time [ Time Frame: From date of transplant through end of follow up, up to 4 years ]
    Analysis of repeated measures of CD4 (cells/mm3) count (longitudinal model)

  12. Trajectory of recipient plasma HIV RNA over time [ Time Frame: From date of transplant through end of follow-up, up to 4 years ]
    Analysis of repeated measures of plasma HIV RNA (copies/mL) longitudinal model

  13. Graft function as assessed by Fibrosis-4 index [ Time Frame: 1 years post-transplant ]
    Mean calculated fibrosis-4 index (Age (years) + AST/platelet count (109/L) x √ALT) Fibrosis 4 index estimates the amount of scar or fibrosis in the liver without requiring a biopsy. Using a lower cutoff value of 1.45, a FIB-4 score <1.45 had a negative predictive value of 90% for advanced fibrosis. In contrast, a FIB-4 >3.25 would have a 97% specificity and a positive predictive value of 65% for advanced fibrosis. In the patient cohort in which this formula was first validated, at least 70% patients had values <1.45 or >3.25.

  14. Graft function as assessed by Fibrosis-4 index [ Time Frame: 2 years post-transplant ]
    Mean calculated fibrosis-4 index (Age (years) + AST/platelet count (109/L) x √ALT) Fibrosis 4 index estimates the amount of scar or fibrosis in the liver without requiring a biopsy. Using a lower cutoff value of 1.45, a FIB-4 score <1.45 had a negative predictive value of 90% for advanced fibrosis. In contrast, a FIB-4 >3.25 would have a 97% specificity and a positive predictive value of 65% for advanced fibrosis. In the patient cohort in which this formula was first validated, at least 70% patients had values <1.45 or >3.25.

  15. Graft function as assessed by Fibrosis-4 index [ Time Frame: 3 years post-transplant ]
    Mean calculated fibrosis-4 index (Age (years) + AST/platelet count (109/L) x √ALT) Fibrosis 4 index estimates the amount of scar or fibrosis in the liver without requiring a biopsy. Using a lower cutoff value of 1.45, a FIB-4 score <1.45 had a negative predictive value of 90% for advanced fibrosis. In contrast, a FIB-4 >3.25 would have a 97% specificity and a positive predictive value of 65% for advanced fibrosis. In the patient cohort in which this formula was first validated, at least 70% patients had values <1.45 or >3.25.

  16. Graft function as assessed by Fibrosis-4 index [ Time Frame: 4 years post-transplant ]
    Mean calculated fibrosis-4 index (Age (years) + AST/platelet count (109/L) x √ALT) Fibrosis 4 index estimates the amount of scar or fibrosis in the liver without requiring a biopsy. Using a lower cutoff value of 1.45, a FIB-4 score <1.45 had a negative predictive value of 90% for advanced fibrosis. In contrast, a FIB-4 >3.25 would have a 97% specificity and a positive predictive value of 65% for advanced fibrosis. In the patient cohort in which this formula was first validated, at least 70% patients had values <1.45 or >3.25.

  17. Graft function as assessed by incidence of fibrosis [ Time Frame: From date of transplant through end of follow-up, up to 3 years ]
    Cumulative incidence of advanced fibrosis (stage F3 or greater as defined by Metavir fibrosis score) as measured on biopsy. The fibrosis score is assessed on a five point scale (F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = few septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis).

  18. Graft function as assessed by liver stiffness [ Time Frame: 1 year post-transplant ]
    Mean calculated liver stiffness by transient elastography (kPA)

  19. Graft function as assessed by liver stiffness [ Time Frame: 2 years post-transplant ]
    Mean calculated liver stiffness by transient elastography (kPA)

  20. Graft function as assessed by liver stiffness [ Time Frame: 3 years post-transplant ]
    Mean calculated liver stiffness by transient elastography (kPA)

  21. Average graft function as assessed by aspartate aminotransferase (AST) [ Time Frame: 1 year post-transplant ]
    Mean calculated AST (U/L)

  22. Average graft function as assessed by AST [ Time Frame: 2 years post-transplant ]
    Mean calculated AST (U/L)

  23. Average graft function as assessed by AST [ Time Frame: 3 years post-transplant ]
    Mean calculated AST (U/L)

  24. Average graft function as assessed by AST [ Time Frame: 4 years post-transplant ]
    Mean calculated AST (U/L)

  25. Average graft function as assessed by alanine aminotransferase (ALT) [ Time Frame: 1 year post-transplant ]
    Mean calculated ALT (U/L)

  26. Average graft function as assessed by ALT [ Time Frame: 2 years post-transplant ]
    Mean calculated ALT (U/L)

  27. Average Graft function as assessed by ALT [ Time Frame: 3 years post-transplant ]
    Mean calculated ALT (U/L)

  28. Average graft function as assessed by ALT [ Time Frame: 4 years post-transplant ]
    Mean calculated ALT (U/L)

  29. Average graft function as assessed by bilirubin [ Time Frame: 1 year post-transplant ]
    Mean calculated bilirubin (mg/dL)

  30. Average graft function as assessed by bilirubin [ Time Frame: 2 years post-transplant ]
    Mean calculated bilirubin (mg/dL)

  31. Average graft function as assessed by bilirubin [ Time Frame: 3 years post-transplant ]
    Mean calculated bilirubin (mg/dL)

  32. Average graft function as assessed by Bilirubin [ Time Frame: 4 years post-transplant ]
    Mean calculated bilirubin (mg/dL)

  33. Graft function as assessed by Mean calculated Model for End Stage Liver Disease (MELD) score [ Time Frame: 1 year post-transplant ]
    Mean calculated MELD score. MELD score indicates the severity of liver disease, with scores ranging from 0-40. The higher the score the more severe the disease

  34. Graft function as assessed by Mean calculated MELD score [ Time Frame: 2 years post-transplant ]
    Mean calculated MELD score. MELD score indicates the severity of liver disease, with scores ranging from 0-40. The higher the score the more severe the disease

  35. Graft function as assessed by Mean calculated MELD score [ Time Frame: 3 years post-transplant ]
    Mean calculated MELD score. MELD score indicates the severity of liver disease, with scores ranging from 0-40. The higher the score the more severe the disease

  36. Graft function as assessed by Mean calculated MELD score [ Time Frame: 4 years post-transplant ]
    Mean calculated MELD score. MELD score indicates the severity of liver disease, with scores ranging from 0-40. The higher the score the more severe the disease

  37. Graft function as assessed by AST to Platelet Ratio (APRI) index [ Time Frame: 1 year post-transplant ]
    Mean calculated APRI index [( AST / upper limits of normal (ULN) AST ) x 100] / Platelets (109/L)] An APRI score greater than 1.0 has a sensitivity of 76% and specificity of 72% for predicting cirrhosis. In addition, APRI score greater than 0.7 has a sensitivity of 77% and specificity of 72% for predicting significant hepatic fibrosis.For detection of cirrhosis, using an APRI cutoff score of 2.0 is more specific (91%) but less sensitive (46%). The lower the APRI score (less than 0.5), the greater the negative predictive value (and ability to rule out cirrhosis) and the higher the value (greater than 1.5) the greater the positive predictive value (and ability to rule in cirrhosis); midrange values are less helpful.

  38. Graft function as assessed by AST to Platelet Ratio (APRI) index [ Time Frame: 2 years post-transplant ]
    Mean calculated APRI index [( AST / ULN AST ) x 100] / Platelets (109/L)] An APRI score greater than 1.0 has a sensitivity of 76% and specificity of 72% for predicting cirrhosis. In addition, APRI score greater than 0.7 has a sensitivity of 77% and specificity of 72% for predicting significant hepatic fibrosis.For detection of cirrhosis, using an APRI cutoff score of 2.0 is more specific (91%) but less sensitive (46%). The lower the APRI score (less than 0.5), the greater the negative predictive value (and ability to rule out cirrhosis) and the higher the value (greater than 1.5) the greater the positive predictive value (and ability to rule in cirrhosis); midrange values are less helpful.

  39. Graft function as assessed by AST to Platelet Ratio (APRI) index [ Time Frame: 3 years post-transplant ]
    Mean calculated APRI index [( AST / ULN AST ) x 100] / Platelets (109/L)] An APRI score greater than 1.0 has a sensitivity of 76% and specificity of 72% for predicting cirrhosis. In addition, APRI score greater than 0.7 has a sensitivity of 77% and specificity of 72% for predicting significant hepatic fibrosis.For detection of cirrhosis, using an APRI cutoff score of 2.0 is more specific (91%) but less sensitive (46%). The lower the APRI score (less than 0.5), the greater the negative predictive value (and ability to rule out cirrhosis) and the higher the value (greater than 1.5) the greater the positive predictive value (and ability to rule in cirrhosis); midrange values are less helpful.

  40. Graft function as assessed by AST to Platelet Ratio (APRI) index [ Time Frame: 4 years post-transplant ]
    Mean calculated APRI index [( AST / ULN AST ) x 100] / Platelets (109/L)] An APRI score greater than 1.0 has a sensitivity of 76% and specificity of 72% for predicting cirrhosis. In addition, APRI score greater than 0.7 has a sensitivity of 77% and specificity of 72% for predicting significant hepatic fibrosis.For detection of cirrhosis, using an APRI cutoff score of 2.0 is more specific (91%) but less sensitive (46%). The lower the APRI score (less than 0.5), the greater the negative predictive value (and ability to rule out cirrhosis) and the higher the value (greater than 1.5) the greater the positive predictive value (and ability to rule in cirrhosis); midrange values are less helpful.

  41. Metabolic Outcome as assessed by Body mass index (BMI) [ Time Frame: 1 year post-transplant ]
    Mean calculated BMI (weight in kilograms/height in meters squared)

  42. Metabolic Outcome as assessed by Body mass index (BMI) [ Time Frame: 2 years post-transplant ]
    Mean calculated BMI(weight in kilograms/height in meters squared)

  43. Metabolic Outcome as assessed by Body mass index (BMI) [ Time Frame: 3 years post-transplant ]
    Mean calculated BMI(weight in kilograms/height in meters squared)

  44. Metabolic Outcome as assessed by Body mass index (BMI) [ Time Frame: 4 years post-transplant ]
    Mean calculated BMI(weight in kilograms/height in meters squared)

  45. Average hemoglobin a1c among participants at 1 year [ Time Frame: 1 years post-transplant ]
    Mean calculated hemoglobin a1c (mg/dL)

  46. Average hemoglobin a1c among participants at 2 years [ Time Frame: 2 years post-transplant ]
    Mean calculated hemoglobin a1c (mg/dL)

  47. Average hemoglobin a1c among participants at 3 years [ Time Frame: 3 years post-transplant ]
    Mean calculated hemoglobin a1c (mg/dL)

  48. Average hemoglobin a1c among participants at 4 years [ Time Frame: 4 years post-transplant ]
    Mean calculated hemoglobin a1c (mg/dL)

  49. Number of HIV breakthroughs [ Time Frame: From date of transplant through end of follow-up, up to 4 years ]
    Measured by local sites' Clinical Laboratory Improvement Amendments (CLIA) certified lab with episode of HIV breakthrough defined as 2 consecutive plasma HIV viral loads >200 copies/mL or one HIV viral load >1000 copies/mL after a period of virologic control post-transplant

  50. Number of opportunistic infections [ Time Frame: From date of transplant through end of follow-up, up to 4 years ]
    Cumulative incidence of opportunistic infections

  51. Number of X4 tropic virus breakthroughs [ Time Frame: From date of transplant through end of follow-up, up to 4 years ]
    Measured by sending virus at time of breakthrough for HIV co-receptor assay

  52. Number of vascular complications [ Time Frame: From date of transplant through year 1 ]
    Number of vascular complications within 1 year of transplant, e.g. thrombosis, aneurysm

  53. Number of surgical complications [ Time Frame: From date of transplant through year 1 ]
    Number of surgical complications within 1 year of transplant, e.g. delayed closure, wound dehiscence

  54. Number of viral-related malignancies [ Time Frame: From date of transplant through end of follow-up, up to 4 years ]
    Number of malignancies as determined by local pathology

  55. Hepatitis C (HCV) sustained viral response post-transplant [ Time Frame: 12 weeks HCV treatment ]
    Proportion of HCV RNA positive recipients that achieve a sustained virologic response week 12 post-treatment (<15 IU/mL) with direct acting antivirals

  56. Number of the formation of de novo donor-specific human leukocyte antigen(HLA) antibodies [ Time Frame: From date of transplant through end of year 1 ]
    Proportion of participants with a de novo donor-specific HLA antibody as measured and reported by local sites' lab

  57. Time to first occurrence of all-cause-mortality or graft failure or renal allograft rejection or HIV breakthrough or HIV virologic failure or AIDS defining illness as a composite measure [ Time Frame: From date of transplant through end of follow-up, up to 4 years ]
    Time to first of any of these events: all-cause-mortality or graft failure or renal allograft rejection or HIV breakthrough or HIV virologic failure or AIDS defining illness



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant meets the standard criteria for liver transplant at the local center.
  • Participants being listed for a simultaneous liver kidney (SLK) are eligible if participants meet the standard criteria for both organs.
  • Participant is able to understand and provide informed consent.
  • Participant meets with an independent advocate per the HIV Organ Policy Equity (HOPE) Act Safeguards and Research Criteria.
  • Documented HIV infection (by any licensed assay or documented history of detectable HIV-1 RNA).*
  • Participant is ≥ 18 years old.
  • Opportunistic complications: prior history of certain opportunistic infections is not an exclusion if the participant has received appropriate therapy and has no evidence of active disease. Medical record documentation should be provided whenever possible.
  • CD4+ T-cell count: ≥ 100/µL within 16 weeks prior to transplant if no history of AIDS-defining infection; or ≥ 200 μL if history of opportunistic infection is present.
  • HIV-1 RNA is below 50 RNA/mL.* Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements > 200 copies/mL. *Organ recipients who are unable to tolerate anti-retroviral therapy (ART) due to organ.

failure or recently started ART may be eligible despite a detectable viral load if safe and effective ART to be used by the recipient after transplantation is described.

  • Participant must have or be willing to start seeing a primary medical care provider with expertise in HIV management.
  • Participant is willing to comply with all medications related to participant's transplant and HIV management.
  • For participants with a history of aspergillus colonization or disease, no current clinical evidence of active disease.
  • Agreement to use contraception.
  • Participant is not suffering from significant wasting (e.g. body mass index < 21) thought to be related to HIV disease.

Exclusion Criteria:

  • Participant has a history of progressive multifocal leukoencephalopathy (PML), or primary central nervous system (CNS) lymphoma.*
  • Participant is pregnant or breastfeeding. (Note: Participants who become pregnant post-transplant will continue to be followed in the study and will be managed per local site practice. Women that become pregnant should not breastfeed.)
  • Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03734393


Contacts
Layout table for location contacts
Contact: Christine Durand, MD 410-955-5684 cdurand2@jhmi.edu
Contact: Dorry Segev, MD,PhD 410-502-6115 dorry@jhmi.edu

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Not yet recruiting
Birmingham, Alabama, United States, 35294
Contact: Jared White, MD       jaredwhite@uabmc.edu   
Principal Investigator: Jared White, MD         
United States, California
University of California, San Diego Not yet recruiting
San Diego, California, United States, 92103
Contact: Saima Aslam, MD       saslam@ucsd.edu   
Principal Investigator: Saima Aslam, MD         
University of California, San Francisco Not yet recruiting
San Francisco, California, United States, 94193
Contact: Jennifer Price, MD         
Principal Investigator: Jennifer Price, MD         
United States, District of Columbia
MedStar Georgetown Transplant Institute Not yet recruiting
Washington, District of Columbia, United States, 20007
Contact: Coleman Smith, MD       coleman.i.smith@gunet.georgetown.edu   
Principal Investigator: Coleman Smith, MD         
United States, Florida
University of Miami Not yet recruiting
Miami, Florida, United States, 33136
Contact: Michele Morris, MD    305-243-4598    mmorris2@med.miami.edu   
Principal Investigator: Michele Morris, MD         
United States, Georgia
Emory University Not yet recruiting
Atlanta, Georgia, United States, 30322
Contact: Valentina Stosor, MD    312-695-5085    v-stosor@northwestern.edu   
Principal Investigator: Valentina Stosor, MD         
United States, Illinois
Northwestern University Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Valentina Stosor, MD       v-stosor@morthwestern.edu   
Principal Investigator: Valentina Stosor, MD         
Rush University Medical Center Not yet recruiting
Chicago, Illinois, United States, 60612
Contact: Carlos A. Santos, MD, MPHS    312-563-6372    carlos_a_santos@rush.edu   
Principal Investigator: Carlos A. Santos, MD, MPHS         
United States, Louisiana
Ochsner Medical Center Not yet recruiting
New Orleans, Louisiana, United States, 70121
Contact: Jonathan Hand, MD         
Principal Investigator: Jonathan Hand, MD         
United States, Maryland
University of Maryland, Institute of Human Virology Not yet recruiting
Baltimore, Maryland, United States, 21201
Contact: Jennifer Husson, MD    410-706-8614    jhusson@ihv.umaryland.edu   
Principal Investigator: Jennifer Husson, MD         
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21205
Contact: Christine Durand, MD    410-955-5684    cdurand2@jhmi.edu   
Principal Investigator: Christine Durand, MD         
United States, Massachusetts
Massachusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Nahel Elias, MD    617-726-0174    elias.nahel@mgh.harvard.edu   
Principal Investigator: Nahel Elias, MD         
United States, Minnesota
University of Minnesota Not yet recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Timothy Pruett, MD         
Principal Investigator: Timothy Pruett, MD         
United States, New York
Icahn School of Medicine at Mount Sinai Not yet recruiting
New York, New York, United States, 10029
Contact: Sander Florman, MD    212-659-8313    sander.florman@mountsinai.org   
Principal Investigator: Sander Florman, MD         
Columbia University Medical Center Not yet recruiting
New York, New York, United States, 10032
Contact: Marcus Pereira, MD    212-305-3839    mp2323@cumc.columbia.edu   
Principal Investigator: Marcus Pereira, MD         
New York University School of Medicine Not yet recruiting
New York, New York, United States, 11016
Contact: Sapna Mehta, MD       sapna.mehta@nyumc.org   
Contact: Elaina Weldon, MSN,NP       elaina.weldon@nyumc.org   
Principal Investigator: Sapna Mehta, MD         
United States, Ohio
University of Cincinnati Not yet recruiting
Cincinnati, Ohio, United States, 45267
Contact: Senu Apewokin, MD         
Principal Investigator: Senu Apewokin, MD         
United States, Pennsylvania
University of Pennsylvania Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Emily Blumberg, MD    215-662-7066    blumbere@pennmedicine.upenn.edu   
Principal Investigator: Emily Blumberg, MD         
UPMC - University of Pittsburgh Medical Center Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Ghady Haidar, MD    412-648-6212    haidarg@upmc.edu   
Principal Investigator: Ghady Haidar, MD         
Sponsors and Collaborators
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Christine Durand, MD Johns Hopkins University

Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT03734393     History of Changes
Other Study ID Numbers: IRB00178771
U01AI138897 ( U.S. NIH Grant/Contract )
First Posted: November 8, 2018    Key Record Dates
Last Update Posted: January 24, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No